Over 10,000 brain-research experts gathered in London in mid-July at the Alzheimer’s Association International Conference, and in one room the mood turned celebratory. The video from first author Dr. Lucía Crivelli, a neuropsychologist at FLENI in Argentina, landed because LatAm-FINGERS did something notably better than earlier prevention trials: it achieved a difference of 0.11 points between the test and control groups’ z-scores, corresponding to a relative 55% improvement in overall brain function at the end of the study.

This is not “we found a miracle.” It is “prevention can move the needle, and the design matters.” LatAm-FINGERS tested a culturally adapted lifestyle intervention aimed at reducing dementia risk factors rather than treating dementia after it develops. The trial included 1,200 participants ages 60 to 77 across multiple Latin American countries, and its results showed statistically improved thinking skills compared with a control group that received only bare-bones support like general health advice. In other words: the intervention worked better than the earlier benchmark, and the audience it targeted looks more like the real world.

To understand why that 0.11 matters to anyone who funds, governs, or builds dementia strategies, zoom out to the incentives. A lot of dementia research money goes toward treatments, but several scientists have pushed for a different pitch: reduce risk before dementia shows up. A major reference point is the Lancet Commission, which through its editions has mapped the evidence on dementia risk factors. The most recent edition, published in 2024, identified 14 factors, including smoking, infrequent social contact, and a lack of physical activity. The commission estimated these risk factors contribute to 45% of dementia cases at a population level. That framing creates a simple strategic logic: if a large chunk of risk is modifiable, prevention trials do not compete with treatments. They attack the pipeline upstream.

Dr. Miia Kivipelto, a professor of clinical geriatrics at the Karolinska Institute in Sweden, pushed that logic into trial design. She told Live Science she wanted to “move on to interventions” to show that doing something can change risk. In Finland, she built the FINGER study, the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability, as a two-year program with 1,260 participants ages 60 to 77. The trial split participants into two groups: one received general health advice at the start and again at six and 12 months. The other received a multipart intervention including meetings with nutritionists for personalized meal plans, brain training, exercise programs, social activities, and metabolic and vascular tests. Brain training alone included 144 sessions over 12 months. Crucially, FINGER tested cognition at the end, not dementia rates, and both groups improved. But the comprehensive intervention produced a headline result that brain function was judged 25% stronger than the control group, driven by a statistical difference in z-scores between groups of just 0.04 points, a magnitude a 2021 review described as “small.”

That “small” label is where LatAm-FINGERS becomes more than a science update. Kivipelto argued the improvement is still significant, comparing it to anti-amyloid treatments. In the U.S., several FDA-approved Alzheimer’s drugs target amyloid, a protein that forms tangles in the brain, and reports have said these drugs marginally slow progression, with statistically small overall effects. So the comparison is uncomfortable but useful: lifestyle-based prevention can produce measurable cognitive change, even if the test-score delta is modest. The question becomes: can better targeting make that delta meaningfully bigger?

Enter the translation trials. A related U.S.-based trial called POINTER repeated the approach. Dr. Gill Livingston, a psychiatrist at University College London who led the 2024 Lancet Commission report, told Live Science the data suggests dementia interventions need to be tailored to the risks participants actually face. In POINTER, 70% of participants had a college degree versus roughly 43% of the wider U.S. population, and Livingston noted that randomized controlled trials often skew toward highly educated people who are interested in health and therefore at less risk of developing dementia. That leaves less room for lifestyle interventions to show big effects: the difference between the test and control groups in POINTER was even smaller than in FINGER, at 0.029 points in z-scores.

LatAm-FINGERS tried to fix that mismatch by designing for the lived reality of its participants. Crivelli, Kivipelto, and Livingston pointed to one key factor in explaining the trial’s relative success: “In Latin America, there are more modifiable risk factors.” The study participants had lower academic attainment and higher cardiometabolic risk factors, such as high BMI, than participants in previous studies. LatAm-FINGERS also tailored the intervention details: dietary advice reflected produce available in each region, exercise programs considered local environmental factors like holding sessions outside and avoiding hot gyms during sweltering summers in Ecuador and Mexico, and the intervention leaned into patterns associated with lower dementia risk such as regular exercise and social interaction. The trial recruited volunteers across Argentina, Brazil, Bolivia, Chile, Colombia, Costa Rica, Ecuador, Mexico, Peru, Puerto Rico, the Dominican Republic, and Uruguay, with 37% having no education beyond a high school diploma compared with just 5% in POINTER. When Crivelli announced the results at the conference, a large cheer filled the room, not because the effect was huge in absolute terms, but because it was larger than prior prevention benchmarks.

For executives and boards, the second-order implication is blunt. If you are evaluating dementia prevention programs, you are not just buying “an intervention.” You are buying the ability to deliver it to the right risk profile, in the right setting, with enough flexibility to adapt nutrition and exercise to local constraints. The LatAm-FINGERS result suggests that the same general strategy can underperform when trial cohorts are unusually protected and can outperform when the program is matched to modifiable risk factors and lower education levels more representative of the broader population. That shifts how stakeholders should think about measurement, scaling, and portfolio allocation. The strategic stake is whether the field can move from “statistically improved cognition” to “repeatable, scalable prevention,” and LatAm-FINGERS is the latest signal that tailoring is not a nice-to-have. It is what turns small effects into something boards can actually bet on.